MIT spinout aims to improve manufacturing of peptides

14 Dec 2023

PDC

Amide Technologies is now marketing its peptide manufacturing technology at a time when peptide-based therapies such as Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro are in high demand. The Cambridge, MA startup, which was spun out of the Massachusetts Institute of Technology in 2016, developed a technology that more quickly synthesizes long chains of amino acids into peptides. CEO Mark Simon said in an interview with Endpoints News that Amide’s tech could help ease the supply crunch for GLP-1 drugs because the company manufactures peptides faster than traditional methods. Lilly and Novo have both reported several manufacturing roadblocks trying to meet the demand for their GLP-1 drugs.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Amide Technologies, Inc.

Novo Nordisk A/S

Eli Orthodontics

[+3]

Indications

Targets

Drugs

TirzepatideBEBT-808

Chat with Hiro

Hot reports

GPRC5D Target Patent Research Report

Patsnap Synapse

Global Drug R&D Express (July 2024)

PatSnap Synapse

siRNA Drug Amvuttra Patent Research and Practical Operation Guide

Patsnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.